The pharmacological bases of the antiangiogenic activity of paclitaxel
Open Access
- 7 February 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Angiogenesis
- Vol. 16 (3), 481-492
- https://doi.org/10.1007/s10456-013-9334-0
Abstract
In the mid 1990s, researchers began to investigate the antiangiogenic activity of paclitaxel as a possible additional mechanism contributing to its antineoplastic activity in vivo. In the last decade, a number of studies showed that paclitaxel has antiangiogenic activity that could be ascribed to the inhibition of either tubule formation or cell migration, and to an antiproliferative effect towards activated endothelial cells. Furthermore, paclitaxel was shown to downregulate VEGF and Ang-1 expression in tumor cells, and to increase the secretion of TSP-1 in the tumor microenvironment. Moreover, the new pharmaceutical formulations of paclitaxel (such as liposome-encapsulated paclitaxel, ABI-007, and paclitaxel entrapped in emulsifying wax nanoparticles) enhanced the in vivo antiangiogenic activity of the drug. Thus, the preclinical data of paclitaxel may be exploited to implement a novel and rational therapeutic strategy to control tumor progression in patients.Keywords
This publication has 74 references indexed in Scilit:
- Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancersAngiogenesis, 2012
- Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approvalOncoTargets and Therapy, 2011
- Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor AngiogenesisMolecular Therapy, 2010
- Antiangiogenic Activity of Sterically Stabilized Liposomes Containing Paclitaxel (SSL-PTX): In Vitro and In VivoAAPS PharmSciTech, 2010
- Antivascular Actions of Microtubule-Binding DrugsClinical Cancer Research, 2009
- Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancerInternational Journal of Nanomedicine, 2009
- A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patientsBritish Journal of Cancer, 2008
- Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeletonMolecular Cancer Therapeutics, 2006
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- ‘Accidental’ anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examplesEuropean Journal of Cancer, 2000